ASX Release
ASX Code: MEM

18 November 2026

Memphasys Completes Successful Initial Felix™ Implementation Phase in Australia

Highlights

- **Memphasys has completed the initial three-month operational assessment phase of Felix™ sperm preparation technology for assisted reproduction at three Monash IVF Group Australian laboratory sites.**
- **Monash IVF Group Limited (Monash IVF) is proceeding with the national rollout of Felix™ across its Australian clinic network. Deployment at each additional clinic will progress as sites are ready and laboratory training requirements are met.**
- **The 12-month exclusive supply agreement announced in June 2026 is progressing from initial assessment to broader commercial deployment.**

Memphasys Limited (ASX: MEM) (Memphasys or the Company) advises that the initial three-month implementation phase under its supply agreement with Monash IVF Group Limited (ASX:MVF) (Monash IVF) has been successfully completed, with Felix™ now in use at three laboratories. Following successful completion of the initial three-month implementation phase, Monash IVF is proceeding with the national rollout of Felix™ across its Australian clinic network. Implementation will be undertaken progressively, with the timing of deployment at each additional clinic determined by individual site readiness and laboratory training requirements.

The original agreement was announced on 16 June 2026. Unit pricing remains confidential. As noted in that announcement, Monash IVF reported 12,085 stimulated IVF cycles in FY2025.

Memphasys Non-Executive Chairman David Tasker commented

“Completing the initial implementation phase is an important step in turning the Monash IVF agreement into a broader commercial rollout. Felix is now in use at three sites and Monash IVF is proceeding with the national rollout.

“Both teams have put considerable work into the past three months to support implementation and prepare for expansion. That practical experience gives us a stronger foundation for introducing Felix across the wider network.

“Our focus now is on supporting the rollout and helping laboratory teams use Felix. For Memphasys, that is how an expanded clinic footprint translates into ongoing cartridge demand.”

Preparing for wider adoption

Memphasys and Monash IVF have worked closely throughout the initial phase to embed Felix™ into participating laboratories and prepare for wider implementation. This collaboration has focused on supporting laboratory teams through the introduction of the system and applying the experience gained at the initial sites to the broader rollout. Felix will be introduced progressively into laboratories, subject to site readiness and laboratory training, for use in clinically appropriate treatment pathways.

The initial phase was designed to cover operational assessment, workflow optimisation and staff training. Completion of this phase is an implementation milestone and does not constitute the announcement of new clinical trial results or patient outcomes.

Memphasys Limited
Level 1, 34-36 Richmond Road
Homebush West, NSW 2140

Contact Details
P +612 8415 7300

E info@memphasys.com
W memphasys.com
ABN 33 120 047 556

The September quarterly report noted that implementation had expanded to an additional clinic and that national deployment remained subject to successful implementation[1]. The completion of the initial phase and Monash IVF's decision to proceed represent the next step in that process.

Commercial rollout under the existing agreement

Following completion of the initial implementation phase, the full 12-month Australian supply term under the agreement announced in June 2026 has now commenced.

Felix™ combines a benchtop console with single-use cartridges to automate sperm selection for assisted reproduction. Expansion across additional sites broadens the installed base from which ongoing cartridge use and repeat orders can develop as clinics utilise the system.

The next stage is implementation across the remaining sites. Revenue will be recognised as supply obligations are satisfied under the applicable accounting requirements.

This announcement has been authorised for release by the Board of Memphasys Limited.

ENDS

For further information, please contact:

Colin Jacoby,
Chapter One Advisors
T: +61 439 980 359
E: cjacoby@chapteroneadvisors.com.au

About Memphasys

Memphasys Limited (ASX: MEM) is an Australian reproductive biotechnology company commercialising the Felix™ System, a patented sperm preparation technology using electrophoresis and size-exclusion membranes to isolate sperm for assisted reproduction. The system comprises a benchtop console and single-use cartridges.

Website: www.memphasys.com

Forward Looking Statements

Statements about the planned rollout, clinic adoption, cartridge demand and future revenue are forward looking and reflect current expectations. They are subject to implementation, timing and commercial risks, and actual outcomes may differ materially. Planned deployment, orders, recognised revenue and cash receipts are distinct measures. Memphasys undertakes no obligation to update forward-looking statements except as required by law.

[1] Memphasys Quarterly Activities Report, 13 October 2026, page 3.